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Objectives: The objectives of this study were to investigate the relation of vascular,
neuropsychiatric, social, and frailty-related factors with “Cognitive impairment, no
dementia” (CIND) and to verify their effect independently of future progression to
Alzheimer disease (AD). Methods: Seven hundred eighteen subjects aged 75 years
who attended baseline, 3- and 6-year follow-up examinations of the Kungsholmen
Project, a Swedish prospective cohort study, were studied. CIND was defined accord-
ing to the performance on the Mini-Mental State Examination. Potential risk factors
were collected at baseline and clustered according to four research hypotheses
(frailty, vascular, neuropsychiatric, and social hypothesis), each representing a pos-
sible pathophysiological mechanism of CIND independently of subsequent develop-
ment of AD. Results: Over a mean 3.4 years of follow up, 82 participants (11.4%)
developed CIND. When the population was subsequently followed for a mean of 2.7
years, subjects with CIND had a threefold increased risk to progress to AD. After
multiple adjustments, including adjustment for the development of AD at the 6-year
follow up, risk factors for CIND were hip fracture, polypharmacy, and psychoses.
Conclusions: The results suggest that not only the AD-type neurodegenerative pro-
cess, but also neuropsychiatric- and frailty-related factors may induce cognitive
impairment in nondemented elderly. These findings may have relevant preventive
and therapeutic implications. (Am J Geriatr Psychiatry 2007; 15:60–69)
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Over the last decade, a great amount of sci-entific effort has focused on early detection
of Alzheimer disease (AD). Individuals who de-
velop a degenerative dementia are likely to un-
dergo a transitional period of cognitive deficits.
The concept of cognitive impairment in nonde-
mented subjects has been raised, and different defi-
nitions with variable prognosis have been used.1
Proposed terms such as “cognitive impairment, no
dementia” (CIND)2,3 and “mild cognitive impair-
ment” (MCI)4 describe cognitive syndromes with
high rates of progression to dementia and AD.
A clinic-based study reported an annual pro-
gression rate to AD of 12% for MCI subjects in
contrast to an annual incidence of dementia of
2% in cognitively intact subjects.4 Similar data
were obtained from population-based studies con-
ducted in subjects with CIND.3,5 However, as pre-
viously reported,6,7 we also found that the out-
come of CIND includes even improvement and
that subjects who improved no longer had an in-
creased risk of developing dementia when subse-
quently followed for three years.3 These findings
suggest that cognitive impairment has heteroge-
nous risk factors.
A comprehensive study of risk factors for cog-
nitive impairment in nondemented subjects may
help in better understanding this heterogeneity, but
few studies have prospectively addressed this is-
sue on a population level. Older age, low education,
being black, depression, apolipoprotein E 4 allele
(ApoE 4), medicated hypertension, midlife ele-
vated serum cholesterol, high diastolic blood pres-
sure, cortical atrophy, brain infarcts, and white
matter hyperintensities have been identified as risk
factors for cognitive impairment in dementia-free
persons.8–11
Within the Kungsholmen Project, we had the
opportunity to investigate the longitudinal asso-
ciation among genetic, clinical, neuropsychiatric,
and social factors and subsequent development of
CIND in an elderly population and to examine
whether the associations were independent of fu-
ture development of AD. Four research hypothe-
ses, each representing possible underlying patho-
physiological mechanisms of CIND apart from in-
cipient AD (i.e., conversion within three years), are
examined.
Frailty Hypothesis
Because frailty-related factors are associated with
low cognitive performance or cognitive impair-
ment,12,13 we hypothesized that physical dependence,
chronic disease, hip fracture, visual and hearing prob-
lems, being underweight, and polypharmacy are risk
factors for CIND.
Vascular Hypothesis
Vascular diseases and factors (e.g., ApoE 4) have
been reported to be associated with cognitive impair-
ment and cognitive decline in nondemented sub-
jects.8–11,14 We hypothesized that heart disease, cere-
brovascular disease, hypertension, diabetes, obesity,
and ApoE 4 increase the risk of CIND.
Neuropsychiatric Hypothesis
Because depressive symptoms and use of psycho-
tropic drugs have been associated with cognitive
decline and cognitive impairment,8,13,15,16 we hy-
pothesized that psychoses, depressive symptoms,
and the use of psychotropic drugs may lead to CIND.
Social Hypothesis
Recent evidence suggests that a socially integrated
lifestyle in late life has a beneficial effect on cogni-
tion.17 We hypothesized that infrequent participation
in leisure activities and a limited social network in-
crease the risk of developing CIND.
METHODS
Study Population
Data were gathered from the Kungsholmen
Project, a longitudinal study of aging and dementia,
including all inhabitants of the Kungsholmen district
of Stockholm, aged 75 years on October 1, 1987.18
Among the 1,700 baseline participants (1987–1989),
225 subjects were prevalent dementia cases and 1,475
were nondemented.18,19 Of those, 212 subjects had
CIND, 31 had low cognitive performance (Mini-
Mental State Examination [MMSE] score 20),20 and
nine were excluded because of missing data on ed-
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ucation or age95 years. Thus, the cognitively intact
cohort at baseline consisted of 1,223 individuals.3 Of
these, 143 moved or refused to attend the first follow
up, which was carried out three years later (1991–
1993),21 218 persons died before the examination,
and 144 developed dementia. The remaining 718
nondemented subjects constituted the study popula-
tion. The Karolinska Institutet Ethics Committee ap-
proved all phases of the Kungsholmen Project, and
written informed consent was obtained from all par-
ticipants at baseline after the procedures had been
fully explained.
Definition of Cognitive Impairment
CIND was defined on the basis of the MMSE.20
Cutoffs for CIND were derived from a previous
study3 and defined as one standard deviation (SD)
below the age- and education-specific mean on the
test.
Baseline Variables
Demographics, Lifestyles, and Functional Characteris-
tics. Data on age and sex were obtained from the
Stockholm municipality office. Education was mea-
sured by total years of formal schooling and dichot-
omized into 8 years and 8 years. Leisure activi-
ties included social, mental, productive, and fitness
activities.22 Social network comprised elements of
marital status, living arrangements, having children,
frequency of contact, and satisfaction with such con-
tact.23 Functional status was measured by Katz’ in-
dex of activity of daily living (ADL).24 Sensory func-
tion was assessed by physician; hearing impairment
was defined as being unable to hear the interviewer’s
voice (even with a hearing aid), and vision impair-
ment included being blind or almost blind.
Clinical Characteristics and ApoE Genotyping. In-
formation on medical drug use in the 2 weeks before
the baseline interview was collected and verified by
inspecting drug containers and prescriptions. Drugs
were coded according to the Anatomical Therapeu-
tical Classification system (ATC).25
Data on medical history were derived from the
computerized Stockholm inpatient registry system,
which encompassed all discharge diagnoses from
hospital admissions in Stockholm since 1969. Dis-
eases from 1969 until baseline were diagnosed ac-
cording to the International Classification of Diseases,
8th and 9th revisions (ICD-8/ICD-9)26,27 as follows:
chronic obstructive pulmonary disease (ICD-8/ICD-9
codes 490–493), anemia (ICD-8/ICD-9 codes 280–
289), malignancy (ICD-8/ICD-9 codes 140–209, 225),
arthritis (ICD-8 codes 713–715; ICD-9 codes 715–716),
hip fracture (ICD-8/ICD-9 code 820), heart disease
(ICD-8 codes 393–398, 410–414, 423–429; ICD-9 codes
393–398, 410–414, 416–417, 423–429), cerebrovascular
disease (ICD-8/ICD-9 codes 430–438), hypertension
(ICD-8/ICD-9 codes 400–404), diabetes mellitus (ICD-8/
ICD-9 code 250), and psychoses (ICD-8/ICD-9 codes
291–298). Clinical diagnoses were grouped as follows:
1. “Vascular disease” included the presence of at
least one of heart disease, cerebrovascular dis-
ease, diabetes, or hypertension. Diabetes melli-
tus was defined as the use of blood glucose-
lowering medications (ATC code: A10) or a
previous diagnosis of diabetes in the inpatient
registry. Hypertension was defined as a previ-
ous diagnosis in the inpatient registry or ac-
cording to blood pressure measurements taken
at baseline (systolic blood pressure 160 mm
Hg or diastolic blood pressure 95 mm Hg).
2. “Chronic disease” included the presence of at
least one of the diseases included in the “vas-
cular disease” group or chronic obstructive
pulmonary disease, anemia, malignancy, or ar-
thritis.
The presence of current depressive symptoms
was assessed by asking the subjects the following
questions: “Do you often feel in a low mood?” and
“Do you often feel lonely/lonesome?” Both ques-
tions belong to the Center for Epidemiological Studies–
Depression Scale.28
Body mass index (BMI) was calculated as the body
weight (in kilograms) divided by the square height
(in meters). Genomic DNA was extracted from pe-
ripheral blood samples, and ApoE genotyping was
carried out using a standard polymerase chain reac-
tion.29
Diagnosis of Dementia and Alzheimer Disease
For baseline and all follow ups, dementia cases
were ascertained by specialists according to Diagnos-
tic and Statistical Manual of Mental Disorders, Third
Edition, Revised criteria30 with a three-step diagnostic
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procedure.18 Briefly, two examining physicians inde-
pendently made a preliminary diagnosis, and a third
opinion was sought in case of disagreement. The AD
diagnosis required gradual onset, progressive dete-
rioration, and lack of any other specific cause of
dementia. For deceased subjects, dementia diagnoses
were made after reviewing the medical records and
death certificates.
Statistical Analysis
Characteristics between subjects with and without
CIND at first follow up were compared with two-
tailed Pearson chi-squared or independent Student
t tests. The progression rates of CIND to AD were
calculated as number of events divided by person-
years of follow up. A Cox proportional hazard model
was constructed to estimate the relative risk (RR)
and 95% confidence intervals (95% CIs) of develop-
ing AD related to CIND. Different logistic regression
models were constructed to estimate odds ratios
(ORs) and 95% CIs of CIND related to each risk
factor examined in the different hypotheses.
Frailty Hypothesis. Putative risk factors were ADL
disability (a score 1), chronic disease, hip fracture,
visual and hearing impairment, being underweight,
and number of drugs used. BMI was categorized as
underweight (BMI 18.5 kg/m2), normal weight or
overweight (BMI 18.5–29.9 kg/m2), or obese (BMI
30 kg/m2).31 BMI was available for 675 (94%) par-
ticipants. Number of drugs was categorized as no
drug use, 1–4 drugs, and polypharmacy (5 drugs).
Vascular Hypothesis. Variables included ApoE 4,
heart disease, cerebrovascular disease, hypertension,
diabetes, and obesity. ApoE genotypes were avail-
able for 626 (87.2%) persons.
Neuropsychiatric Hypothesis. Factors included
psychoses, depressive symptoms, and psychotropic
drug use. For depressive symptoms, a combined di-
chotomized variable was created, in which having
none of both symptoms was coded as 0 and having
one or two symptoms was coded as 1. Drugs in-
cluded neuroleptics (ATC code: N05A), anxiolytics
(ATC code: N05B), other tranquilizers and hypnotics
(ATC code: N05C), and antidepressants (ATC code:
N06A).
Social Hypothesis. Variables included social, men-
tal, productive, and fitness activities and social net-
work. Concerning leisure activities, participation in
mental and fitness activities was dichotomized into
frequent (daily) versus no/infrequent (no/less than
daily).22 Participation in social and productive activ-
ities was dichotomized into frequent (daily/weekly)
versus no/infrequent (no/less than weekly).22 The
previously used four-grade social network summary
index was dichotomized into moderate/extensive
versus poor/limited social network.23
For each hypothesis, three different logistic regres-
sion models were initially implemented: the unad-
justed model; the basic-adjusted model with age, sex,
education, and time to first follow-up; and the mul-
tiple-adjusted model with further control for con-
founders specific to each hypothesis. In the last
model age, sex, education, and time to first follow up
represented common confounders for the four re-
search hypotheses. Further factors entered in the
frailty hypothesis as confounders were depressive
symptoms, social network, and ApoE 4; specific
confounders for the vascular hypothesis were depres-
sive symptoms, chronic obstructive pulmonary dis-
ease, anemia, malignancy, and arthritis; for the neu-
ropsychiatric hypothesis, confounders were social
network, ApoE 4, ADL disability, and chronic dis-
ease; specific confounders for the social hypothesis
were depressive symptoms, ADL disability, and
chronic disease.
Finally, we further adjusted for the development
of AD at the second follow up (three years after
CIND occurrence, 1994–1996) to verify whether the
effect of various factors was independent of the AD-
type neurodegenerative process. As a result of re-
fusal at second follow up (N41) and exclusion of
other dementias (N26), the study sample for these
analyses consisted of 651 (90.7%) subjects.
Because the results from the unadjusted and basic-
adjusted models overlapped with those from the
multiple-adjusted models, we report only the results
from the latter.
RESULTS
Of the 718 subjects that were cognitively intact at
baseline, 82 (11.4%) developed CIND at first follow
up. The mean follow-up time was 3.4 years (SD: 0.5)
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without significant difference between subjects with
(3.30.5 years) and without (3.40.5 years) CIND
(Student t-test716  1.192; p0.23). At baseline,
subjects who developed CIND at first follow up were
older and more often reported no/infrequent social
and mental activities than cognitively intact subjects
(Table 1).
Individuals with CIND had significantly higher
prevalence of hip fracture and psychoses and more
often used polypharmacy or had depressive symp-
toms than subjects without CIND (Table 2).
Among the 82 CIND subjects, 20 were diagnosed
with AD at the second follow up, with a crude inci-
dence rate of 11.6 per 100 person-years. Of the 636
subjects without CIND, 66 had AD at the second
follow up, with a crude incidence rate of 4.0 per 100
person-years. Subjects with CIND had an age, sex,
and education adjusted RR of 2.8 (95% CI: 1.7–4.6;
Wald 2[1]  16.7; p 0.0001) to develop AD. The
mean follow-up time for the 651 subjects followed at
the second follow up was 2.7 years (SD: 0.9) with a
significant difference between subjects with (2.41.0
years) and without (2.8  0.9 years) CIND at first
follow up (Student t-test[649]2.993; p0.004).
Frailty Hypothesis
Hip fracture and polypharmacy were associated
with nearly a threefold increase in the risk of devel-
oping CIND, even after controlling for future devel-
opment of AD (Table 3).
Vascular Hypothesis
None of the vascular risk factors from the hypoth-
esis were significantly associated with the develop-
ment of CIND, even after adjustment for subsequent
development of AD (Table 4).
Neuropsychiatric Hypothesis
Previous psychoses increased the risk of CIND
nearly sevenfold. Adjustment for future develop-
ment of AD did not significantly alter this result
(Table 5). Depressive symptoms increased the risk of
CIND. However, when subsequent development of
ADwas entered in the model, this association was no
longer significant (Table 5).
Social Hypothesis
No/infrequent social activities almost increased
the risk of CIND, but this was no longer significantly
present when future AD was entered in the model
(Table 5).
DISCUSSION
This study confirms that CIND is characterized
by heterogenous risk factors.8,10 Psychoses, poly-
pharmacy, and hip fracture increased the risk
TABLE 1. Baseline Demographic, Lifestyle, and Functional Characteristics of Subjects With and Without Cognitive Impairment,
No Dementia (CIND) at Three-Year Follow Up
CIND No CIND
Baseline Characteristic (N  82)a (N  636)a Analyses p
Age, years (mean, SD) 81.6 (4.5) 80.3 (4.3) t [716]  2.4 0.020
Female gender 61 (74.4) 471 (74.1) 2 [1]  0.004 0.948
8 years of education 47 (57.3) 341 (53.6) 2 [1]  0.4 0.527
No/infrequent engagement in
Social activities 48 (58.5) 289 (45.4) 2 [1]  5.0 0.025
Mental activities 24 (29.3) 117 (18.4) 2 [1]  5.4 0.020
Productive activities 52 (63.4) 406 (63.8) 2 [1]  0.006 0.940
Fitness activities 70 (85.4) 551 (86.6) 2 [1]  0.1 0.752
Poor/limited social network 13 (15.9) 119 (18.7) 2 [1]  0.4 0.530
Activities of daily living disability 19 (23.2) 122 (19.2) 2 [1]  0.7 0.392
Vision problems 32 (39.0) 223 (35.4) 2 [1]  0.4 0.519
Hearing problems 32 (39.5) 253 (40.4) 2 [1]  0.02 0.884
aValues are N (%) unless otherwise indicated.
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of CIND independently of subsequent devel-
opment of clinical AD. However, subjects with
CIND were at increased risk of developing AD.
These findings suggest that CIND is not only
a transitional phase between normal aging
and AD, but a syndrome with multiple risk factors.
TABLE 2. Baseline Clinical Characteristics and Apolipoprotein E 4 Allele of Subjects With and Without Cognitive Impairment,
No Dementia (CIND) at Three-Year Follow Up
Baseline Characteristic
CIND
(N82)
No CIND
(N636) 2 [df] p
N (%) N (%)
Number of drugs used 7.3[2] 0.026
0 9 (11.0) 125 (19.7)
1–4 46 (56.1) 375 (59.0)
5 27 (32.9) 136 (21.4)
Chronic obstructive pulmonary disease 1 (1.2) 23 (3.6) 1.3[1] 0.256
Anemia 2 (2.4) 19 (3.0) 0.08[1] 0.781
Malignancy 7 (8.5) 56 (8.8) 0.07[1] 0.936
Arthritis 5 (6.1) 32 (5.0) 0.2[1] 0.681
Hip fracture 8 (9.8) 24 (3.8) 6.1[1] 0.013
Vascular disease 48 (58.5) 387 (60.8) 0.2[1] 0.687
Heart disease 13 (15.9) 83 (13.1) 0.5[1] 0.483
Cerebrovascular disease 5 (6.1) 24 (3.8) 1.0[1] 0.314
Hypertension 45 (54.9) 323 (50.8) 0.5[1] 0.485
Diabetes 4 (4.9) 20 (3.1) 0.7[1] 0.411
Chronic disease 52 (63.4) 431 (67.8) 0.6[1] 0.429
Psychoses 4 (4.9) 5 (0.8) 9.8[1] 0.002
Use of psychotropic drugs 30 (36.6) 216 (34.0) 0.2[1] 0.638
Depressive symptoms 33 (40.2) 165 (25.9) 7.4[1] 0.006
Body mass index (kg/m2) 0.4[2] 0.818
18.5 3 (4.1) 29 (4.8)
18.5–29.9 67 (90.5) 548 (91.2)
30 4 (5.4) 24 (4.0)
Apolipoprotein E 4 allele (any versus no) 19 (27.9) 138 (24.7) 0.33[1] 0.564
Note: The following variables have missing values: body mass index (N43) and apolipoprotein E 4 (N92).
TABLE 3. Frailty Hypothesis for the Development of Cognitive Impairment, No Dementia (CIND): Odds Ratio (OR) and 95%
Confidence Intervals (CIs) for Each of the Frailty-Related Factors
Multiadjustmenta
Future Development of Alzheimer Disease
Added to the Modelb
Risk Factor OR (95% CI) Wald 2 [df] p OR (95% CI) Wald 2 [df] p
Activities of daily living disability 1.1 (0.6–2.0) 0.1[1] 0.727 1.2 (0.6–2.2) 0.2[1] 0.649
Chronic disease 0.7 (0.4–1.1) 2.5[1] 0.115 0.6 (0.4–1.1) 2.7[1] 0.099
Hip fracture 2.8 (1.1–6.9) 5.0[1] 0.026 2.9 (1.1–7.8) 4.3[1] 0.037
Visual problems 1.0 (0.6–1.6) 0.3[1] 0.603 1.0 (0.6–1.7) 0.05[1] 0.817
Hearing problems 0.9 (0.5–1.4) 0.004[1] 0.950 0.9 (0.6–1.6) 0.0001[1] 0.986
Body mass index (kg/m2)
18.5 0.6 (0.2–2.2) 0.6[1] 0.432 1.0 (0.3–3.6) 0.0001[1] 0.996
18.5–29.9 1.0 1.0
30 1.6 (0.5–4.9) 0.6[1] 0.439 1.5 (0.4–5.7) 0.4[1] 0.523
Number of drugs used
0 1.0 1.0
1–4 1.6 (0.8–3.5) 1.7[1] 0.197 2.1 (0.9–5.0) 2.9[1] 0.088
5 2.6 (1.1–6.1) 5.0[1] 0.025 3.1 (1.2–8.0) 5.5[1] 0.019
aOR was adjusted for age, sex, education, time to first follow up, depressive symptoms, social network, apolipoprotein E 4 allele (any versus
no), and other variables listed in the table.
bOR was further adjusted for diagnosis of Alzheimer disease made at the second follow-up.
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Frailty Hypothesis
Among the frailty-related factors, only hip fracture
and number of drugs significantly increased the risk
of CIND after controlling for future AD. Potential
mechanisms underlying these findings could be im-
mobility resulting from hip fracture, which can
lead to thromboembolic complications resulting in
silent brain ischemic infarcts causing cognitive de-
cline.32
Number of drugs used was associated with an
increased risk of developing CIND in a dose-
response manner, because the risk steadily increased
from use of 1–4 drugs to 5 drugs. Polypharmacy
can be considered an index of comorbidity,33 and
our findings of a threefold increased risk for CIND
among persons taking 5 drugs strengthens pre-
vious reports that comorbidity is associated with
cognitive performance in nondemented subjects.12
Another possible explanation is that polypharmacy
per se might cause cognitive deficits.13
TABLE 4. Vascular Hypothesis for the Development of Cognitive Impairment, No Dementia (CIND): Odds Ratio (OR) and 95%
Confidence Intervals (CIs) for Each of the Vascular-Related Factors
Multiadjustmenta
Future Development of Alzheimer
Disease Added to the Model b
Risk Factor OR (95% CI) Wald 2 [df] p OR (95% CI) Wald 2 [df] p
Heart disease 1.1 (0.5–2.1) 0.04[1] 0.833 1.0 (0.5–2.1) 0.001[1] 0.978
Cerebrovascular disease 1.4 (0.5–3.9) 0.3[1] 0.559 0.8 (0.2–3.0) 0.1[1] 0.748
Hypertension 1.2 (0.8–2.0) 0.7[1] 0.417 1.2 (0.7–1.9) 0.4[1] 0.547
Diabetes 1.4 (0.4–4.5) 0.3[1] 0.564 1.1 (0.3–4.2) 0.03[1] 0.862
Body mass index (kg/m2)
18.5 0.8 (0.2–2.7) 0.2[1] 0.691 1.1 (0.3–3.8) 0.1[1] 0.899
18.5–29.9 1.0 1.0
30 1.4 (0.4–4.3) 0.3[1] 0.576 1.4 (0.4–5.2) 0.3[1] 0.576
Apolipoprotein E 4 allele (any versus no) 1.2 (0.7–2.2) 0.5[1] 0.470 1.5 (0.8–2.7) 1.6[1] 0.212
aOR was adjusted for age, sex, education, time to first follow up, depressive symptoms, chronic obstructive pulmonary disease, anemia,
malignancy, and arthritis, and other variables listed in the table.
bOR was further adjusted for diagnosis of Alzheimer disease made at the second follow-up.
TABLE 5. Neuropsychiatric and Social Hypotheses for the Development of Cognitive Impairment, No Dementia (CIND): Odds
Ratio (OR) and 95% Confidence Intervals (CIs) for Each of the Neuropsychiatric- and Social-Related Factors
Multiadjustmenta
Future Development of Alzheimer
Disease Added to the Modelb
Risk Factor OR (95% CI) Wald 2 [df] p OR (95% CI) Wald 2 [df] p
Neuropsychiatric hypothesis
Psychoses 6.9 (1.8–27.3) 7.6[1] 0.006 5.0 (1.1–23.6) 4.1[1] 0.042
Depressive symptoms 1.9 (1.1–3.1) 6.0[1] 0.015 1.3 (0.8–2.3) 1.0[1] 0.317
Psychotropic drugs use 0.9 (0.6–1.5) 0.09[1] 0.770 0.9 (0.5–1.6) 0.07[1] 0.798
Social hypothesis
No/Infrequent social activities 1.6 (1.0–2.6) 3.6[1] 0.059 1.4 (0.8–2.3) 1.2[1] 0.270
No/Infrequent mental activities 1.5 (0.9–2.6) 2.1[1] 0.151 1.5 (0.8–2.7) 1.6[1] 0.212
No/Infrequent productive activities 0.8 (0.5–1.4) 0.5[1] 0.469 0.7 (0.4–1.1) 2.3[1] 0.132
No/Infrequent fitness activities 0.7 (0.4–1.4) 1.0[1] 0.322 0.6 (0.3–1.4) 1.4[1] 0.235
Poor/limited social network 0.8 (0.4–1.5) 0.4[1] 0.506 0.8 (0.4–1.6) 0.3[1] 0.562
aNeuropsychiatric hypothesis: OR was adjusted for age, sex, education, time to first follow up, social network, apolipoprotein E 4 allele (any
versus no), activities of daily living disability, chronic disease, and other variables listed in the table. Social hypothesis: OR was adjusted for age,
sex, education, time to first follow up, depressive symptoms, activities of daily living disability, chronic disease, and other variables listed in the
table.
bFor both hypotheses, OR was further adjusted for diagnosis of Alzheimer disease made at the second follow-up.
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Vascular Hypothesis
No associations were found between vascular risk
factors and the development of CIND in contrast to
previous studies.8–11 This lack of replication might
be the result of various reasons. First, the sample size
may be not large enough to detect a weak associa-
tion. Second, previous prospective studies investi-
gating risk factors of MCI were carried out in
younger populations.8–11 The risk effect of vascular
diseases on cognitive impairment may be underesti-
mated in the very old as a result of, for example,
selective survival (e.g., very old people with vascular
comorbidity might have died during the follow-up
period, thus being excluded from the analyses).
Third, the inpatient registry system may fail to catch
some mild cases of vascular disorders (e.g., heart
disease and diabetes), which will lead to a dilution of
the estimation of the associations.34,35 Fourth, as a
result of lack of neuroimaging in our study, the
possible effect of silent brain infarctions was not
taken into account.32
Neuropsychiatric Hypothesis
Previous psychosis was the major risk factor asso-
ciated with the development of CIND after control-
ling for the AD-type neurodegenerative process. Psy-
chotic symptoms and long-term therapy with
antipsychotic medication may lead to cognitive im-
pairment and dementia.13,36 Depressive symptoms
were also related to the development of CIND three
years later. These data confirm recent findings of an
association between depression and MCI.8 However,
our data show that the effect of depressive symp-
toms on CIND is dependent on the subsequent de-
velopment of AD, suggesting that the neurodegen-
erative process underlying the disease may mediate
this association. This finding is in line with previous
reports in which depressive symptoms occurring
more than 25 years before diagnosis were found to be
associated with an increased risk of developing
AD.37 Alternatively, depression may be an early sign
of AD and cognitive decline.38
Social Hypothesis
Subjects who engaged less frequently in social
and mental activities tended to have an increased
risk of developing CIND. However, this trend for
an association disappeared after controlling for
future development of AD. These findings agree
with evidence demonstrating that a healthy social
life can protect against the development of demen-
tia.17,22,39
The strengths of our study are the population-
based prospective design, the comprehensive ana-
lysis of risk factors organized into different etio-
logic hypotheses, and the adjustment for multiple
potential confounders and the ongoing AD-type
neurodegenerative process. However, some meth-
odological issues deserve mentioning. First, CIND
was determined in persons aged 75 years at
entry. Therefore, our results may not be generaliz-
able to a younger elderly population. Second, in-
formation on medical history was mainly taken
from the inpatient register system, which would
identify more severe cases and miss mild cases.
However, our inpatient register covered up to six
diseases diagnosed per hospital admission; this may
have reduced the possibility of missing information.
Third, we could have missed some associations re-
sulting from limited statistical power such as the
association with vascular factors. Fourth, CIND was
defined according to performance on the MMSE,
rather than on clinical judgment, and this could be
considered an imprecise measurement of cognitive
impairment. However, our previous data showed that
this CIND definition significantly predicts dementia
over three and six years3 with a similar proportion
of progression rates as other clinical definitions of
cognitive impairment.40 Fifth, because our analyses
were exploratory, based on preestablished hypotheses,
and run in different models of logistic regression, we
did not control for multiple comparisons. Finally, AD
was diagnosed according to clinical judgment with-
out autopsy confirmation with uncertainty concerning
the rate of diagnostic misclassification.
In conclusion, our study shows that CIND has
heterogenous risk factors, in which different patho-
physiological mechanisms may be involved. CIND
is not only a transitional phase between normal
aging and AD, but a syndrome with multiple risk
factors in which frailty-related factors and psychiatric
disorders seem to play a major role. These findings
may have relevant preventive and therapeutic implica-
tions.
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